CERo Therapeutics Sells Operating Subsidiary to SRX Global in Debt-for-Asset Deal
CEROW sits 95% above its 52-week low of $0.001.
Summary
CERo Therapeutics Holdings agreed to sell its wholly-owned operating subsidiary to SRX Global in exchange for $1M in SRX stock, forgiveness of $8.25M in secured debt, and assumption of ~$1.56M in liabilities. A 30-day go-shop period allows competing bids.
Key Events · M&A and Partnerships · CEROW
-
Subsidiary Sale to SRX Global
CERo Therapeutics Holdings agreed to sell all outstanding capital stock of its wholly-owned operating subsidiary, CERo Therapeutics, Inc., to SRX Global Inc. under a Stock Purchase Agreement dated October 6, 2026.
-
Consideration: Debt Forgiveness + $1M Stock
At closing, Holdings receives $1,000,000 in SRX common stock (share count based on the lower of the last closing price or 20-day VWAP), full forgiveness of the $8,249,643.77 outstanding principal on the Consolidated Note, and SRX's assumption of approximately $1,562,000 in specified liabilities.
-
No Stockholder Vote Required
The board determined the sale qualifies under DGCL Section 272 as an alternative sale of pledged collateral in lieu of foreclosure, with the fair market value of the shares not exceeding the secured liabilities being eliminated — so no common stockholder vote is required.
-
30-Day Go-Shop Period
A 30-day go-shop period runs from signing, during which Joseph Gunnar & Co. will solicit alternative acquisition proposals. A Superior Proposal must repay the Consolidated Note in full, release liens, and pay the $750,000 termination fee.
Analysis · CEROW · Life Sciences
CERo Therapeutics Holdings is selling its only operating subsidiary — the clinical-stage biopharmaceutical company developing lead candidate CER-1236 — to SRX Global Inc. in exchange for $1 million in SRX stock, full forgiveness of $8.25 million in secured debt, and assumption of roughly $1.56 million in liabilities. The deal is structured as a sale of pledged collateral under DGCL Section 272, meaning no common stockholder vote is required. A 30-day go-shop period gives the board a window to seek a superior offer, with a $750,000 termination fee if one emerges. For a company with a market cap under $1 million and a stock trading at $0.00214, this transaction effectively transfers the entire operating business to its secured lender while extinguishing the debt overhang — but leaves common stockholders with only a pro-rata interest in $1 million of SRX shares, the value of which depends on SRX's own stock price and a 180-day lock-up.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 46.1% of the 284 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CEROW was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $737.3K. The 52-week trading range was $0.00 to $0.06. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.